Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer cells.

Yi, Yong Weon

Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer cells. [electronic resource] - Journal of cellular and molecular medicine May 2013 - 648-56 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1582-4934

10.1111/jcmm.12046 doi


Antineoplastic Combined Chemotherapy Protocols--pharmacology
Breast Neoplasms--drug therapy
Caspases--metabolism
Cell Death--drug effects
Cell Line, Tumor
Drug Synergism
ErbB Receptors--antagonists & inhibitors
Extracellular Signal-Regulated MAP Kinases--metabolism
Female
Furans--pharmacology
Gefitinib
Humans
Inhibitory Concentration 50
Phosphatidylinositol 3-Kinases--metabolism
Phosphoinositide-3 Kinase Inhibitors
Protein Kinase Inhibitors--pharmacology
Proto-Oncogene Proteins c-akt--antagonists & inhibitors
Pyridines--pharmacology
Pyrimidines--pharmacology
Quinazolines--pharmacology
Signal Transduction--drug effects